Fentanyl POC Test Instrument Gets FDA Clearance
Shenzhen Superbio Technology received FDA clearance for a point-of-care instrument intended for the detection of fentanyl in human urine.
Shenzhen Superbio Technology received FDA clearance for a point-of-care instrument intended for the detection of fentanyl in human urine.
The March/April 2023 Tech Guide that appears in Clinical Lab Products (CLP) features a wide range of products from top laboratory providers.
A new study suggests that a simple urine test could help reveal if someone has early-stage Alzheimer’s disease.Â
To curb false positives of illegal drug use, researchers in Japan are enabling technology that offers selective screening and analysis of stimulants.
Read MoreA prostate cancer urine test can identify men at intermediate risk who can safely avoid immediate treatment and benefit from active surveillance instead.
Read MoreTimely toxicology testing remains vital to patient treatment, but the challenge is staying ahead of emerging illicit drugs.
Read MoreBeckman Coulter launched its DxU Iris Workcell today at the 2021 AACC Annual Scientific Meeting & Clinical Lab Expo in Atlanta.
Read MorePromis Diagnostics recently presented data for CystoChek, a proprietary urine-based DNA methylation test of PENK for bladder cancer detection in hematuria.
Read MoreTo measure urine sugar levels in elderly or long-term care patients, sensors can be embedded directly into their diapers.
Read MoreCarolina Liquid Chemistries Corp. has launched MyPOCtest.com, an e-commerce website to help supply medical facilities with POC rapid tests.
Read MorePatients undergoing surgery and other procedures are routinely pre-screened for UTIs, but the vast majority of these tests are not needed.
Read MoreADXBLADDER, a urinary biomarker test for bladder cancer, is currently undergoing clinical trials in the U.S.
Read MoreThe FDA awarded AnchorDx a Breakthrough Device Designation for UriFind, an early detection test for bladder cancer based on urine DNA methylation detection.
Read MoreMIT engineers have created a diagnostic nanoparticle that can identify cancer through a urine test and act as an imaging agent, pinpointing the tumor location.
Read MoreNew Jersey Urology (NJU) unveiled its newly renovated pathology laboratory, which offers a menu of services, including NGS and PCR testing.
Read MoreThe urine test, which is expected to be available by mid-2022, will use highly sensitive liquid biopsy technology developed by Nonacus and a panel of biomarkers validated by Birmingham University researchers to diagnose bladder cancer.
Read MoreMagellan Diagnostics is recalling its LeadCare II, LeadCare Plus, and LeadCare Ultra Blood Lead Tests due to a significant risk of falsely low results. The FDA has deemed it a Class I recall.
Read MoreA recent study by Nagoya University researchers revealed that microRNAs in urine could be a promising biomarker to diagnose brain tumors.
Read More